ADORA2A and early-onset autosomal dominant Alzheimer disease: The inhibition of the A2A adenosine receptor has been shown to be beneficial in animal models of Huntington’s and Alzheimer’s disease, epilepsy, and excitotoxic situations such as ischemia, and it is also a strategy used to treat PD [10,11,12,13].